Venbio Global Strategic Fund Iii, L.p. - Net Worth and Insider Trading

Venbio Global Strategic Fund Iii, L.p. Net Worth

The estimated net worth of Venbio Global Strategic Fund Iii, L.p. is at least $35 Million dollars as of 2024-11-05. Venbio Global Strategic Fund Iii, L.p. is the 10% Owner of Artiva Biotherapeutics Inc and owns about 1,936,637 shares of Artiva Biotherapeutics Inc (ARTV) stock worth over $23 Million. Venbio Global Strategic Fund Iii, L.p. is the of Ventyx Biosciences Inc and owns about 5,011,536 shares of Ventyx Biosciences Inc (VTYX) stock worth over $11 Million. Venbio Global Strategic Fund Iii, L.p. is also the 10% Owner of Elevation Oncology Inc and owns about 1,905,430 shares of Elevation Oncology Inc (ELEV) stock worth over $1 Million. Details can be seen in Venbio Global Strategic Fund Iii, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Venbio Global Strategic Fund Iii, L.p. has not made any transactions after 2024-07-22 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Venbio Global Strategic Fund Iii, L.p.

To

Venbio Global Strategic Fund Iii, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Venbio Global Strategic Fund Iii, L.p. owns 3 companies in total, including Elevation Oncology Inc (ELEV) , Ventyx Biosciences Inc (VTYX) , and RayzeBio inc (RYZB) .

Click here to see the complete history of Venbio Global Strategic Fund Iii, L.p.’s form 4 insider trades.

Insider Ownership Summary of Venbio Global Strategic Fund Iii, L.p.

Ticker Comapny Transaction Date Type of Owner
ELEV Elevation Oncology Inc 2022-05-25 10 percent owner
VTYX Ventyx Biosciences Inc 2021-10-25 10 percent owner & other: See Remarks
RYZB RayzeBio inc 2023-09-14 10 percent owner

Venbio Global Strategic Fund Iii, L.p. Latest Holdings Summary

Venbio Global Strategic Fund Iii, L.p. currently owns a total of 3 stocks. Among these stocks, Venbio Global Strategic Fund Iii, L.p. owns 1,936,637 shares of Artiva Biotherapeutics Inc (ARTV) as of July 22, 2024, with a value of $23 Million and a weighting of 65.96%. Venbio Global Strategic Fund Iii, L.p. owns 5,011,536 shares of Ventyx Biosciences Inc (VTYX) as of October 25, 2021, with a value of $11 Million and a weighting of 31.12%. Venbio Global Strategic Fund Iii, L.p. also owns 1,905,430 shares of Elevation Oncology Inc (ELEV) as of May 25, 2022, with a value of $1 Million and a weighting of 2.92%.

Latest Holdings of Venbio Global Strategic Fund Iii, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ARTV Artiva Biotherapeutics Inc 2024-07-22 1,936,637 11.93 23,104,079
VTYX Ventyx Biosciences Inc 2021-10-25 5,011,536 2.18 10,900,091
ELEV Elevation Oncology Inc 2022-05-25 1,905,430 0.54 1,023,025

Holding Weightings of Venbio Global Strategic Fund Iii, L.p.


Venbio Global Strategic Fund Iii, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Venbio Global Strategic Fund Iii, L.p. has made a total of 1 transactions in Artiva Biotherapeutics Inc (ARTV) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Artiva Biotherapeutics Inc is the acquisition of 416,666 shares on July 22, 2024, which cost Venbio Global Strategic Fund Iii, L.p. around $5 Million.

According to the SEC Form 4 filings, Venbio Global Strategic Fund Iii, L.p. has made a total of 1 transactions in Ventyx Biosciences Inc (VTYX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Ventyx Biosciences Inc is the acquisition of 312,500 shares on October 25, 2021, which cost Venbio Global Strategic Fund Iii, L.p. around $5 Million.

According to the SEC Form 4 filings, Venbio Global Strategic Fund Iii, L.p. has made a total of 1 transactions in Elevation Oncology Inc (ELEV) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Elevation Oncology Inc is the sale of 702,737 shares on May 25, 2022, which brought Venbio Global Strategic Fund Iii, L.p. around $3 Million.

Insider Trading History of Venbio Global Strategic Fund Iii, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Venbio Global Strategic Fund Iii, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Venbio Global Strategic Fund Iii, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Venbio Global Strategic Fund Iii, L.p. is -12.42%. GuruFocus also compares Venbio Global Strategic Fund Iii, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Venbio Global Strategic Fund Iii, L.p. within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Venbio Global Strategic Fund Iii, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Venbio Global Strategic Fund Iii, L.p.

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -4.12 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -5.66 LIMIT LIMIT LIMIT LIMIT LIMIT

Venbio Global Strategic Fund Iii, L.p. Ownership Network

Ownership Network List of Venbio Global Strategic Fund Iii, L.p.

No Data

Ownership Network Relation of Venbio Global Strategic Fund Iii, L.p.

Insider Network Chart

Venbio Global Strategic Fund Iii, L.p. Owned Company Details

What does Elevation Oncology Inc do?

Who are the key executives at Elevation Oncology Inc?

Venbio Global Strategic Fund Iii, L.p. is the 10 percent owner of Elevation Oncology Inc. Other key executives at Elevation Oncology Inc include CHIEF FINANCIAL OFFICER Tammy Furlong , 10 percent owner Robert J Adelman , and 10 percent owner Venbio Global Strategic Gp Iii, L.p. .

Elevation Oncology Inc (ELEV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Elevation Oncology Inc (ELEV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Elevation Oncology Inc (ELEV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Elevation Oncology Inc (ELEV)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Elevation Oncology Inc Insider Transactions

No Available Data

Venbio Global Strategic Fund Iii, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Venbio Global Strategic Fund Iii, L.p.. You might contact Venbio Global Strategic Fund Iii, L.p. via mailing address: 1700 Owens Street, Suite 595, San Francisco Ca 94158.